GRIGUOLO, GAIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.454
EU - Europa 474
AS - Asia 415
SA - Sud America 4
AF - Africa 2
OC - Oceania 1
Totale 4.350
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.445
IT - Italia 231
SG - Singapore 179
CN - Cina 170
FI - Finlandia 58
SE - Svezia 53
GB - Regno Unito 31
DE - Germania 29
FR - Francia 29
IN - India 26
HK - Hong Kong 20
CZ - Repubblica Ceca 10
CA - Canada 9
IE - Irlanda 7
PH - Filippine 7
ES - Italia 5
MK - Macedonia 5
BR - Brasile 4
NL - Olanda 4
BE - Belgio 3
JP - Giappone 3
UA - Ucraina 3
IL - Israele 2
IR - Iran 2
TR - Turchia 2
AL - Albania 1
AT - Austria 1
AU - Australia 1
CH - Svizzera 1
DK - Danimarca 1
EG - Egitto 1
HR - Croazia 1
KR - Corea 1
KZ - Kazakistan 1
MY - Malesia 1
OM - Oman 1
RU - Federazione Russa 1
SC - Seychelles 1
Totale 4.350
Salva come PNG Salva come JPEG
Città #
Fairfield 574
Ashburn 506
Chandler 384
Woodbridge 275
Houston 223
Cambridge 213
Seattle 183
Ann Arbor 175
Wilmington 170
Singapore 146
Padova 81
San Diego 73
Medford 52
Princeton 52
Beijing 48
Helsinki 48
Des Moines 41
Roxbury 30
Santa Clara 29
Boardman 19
Milan 17
New York 17
Pune 17
Falls Church 16
London 16
Nanjing 16
Rome 16
Dallas 10
Jinan 10
Codogno 9
Olomouc 8
Ottawa 8
Shenyang 8
Zhengzhou 8
Dublin 7
Selvazzano Dentro 7
Washington 7
Hong Kong 6
Lappeenranta 6
Nanchang 6
Changsha 5
Los Angeles 5
Skopje 5
Tianjin 5
Capo d'Orlando 4
Chiswick 4
Council Bluffs 4
Guangzhou 4
Norwalk 4
Ogden 4
Paris 4
Redwood City 4
Turin 4
Amsterdam 3
Barcelona 3
Brussels 3
Falkenstein 3
Haikou 3
Hamburg 3
Springfield 3
Taizhou 3
Venice 3
Verona 3
Ancona 2
Avezzano 2
Bergamo 2
Bursa 2
Caserta 2
Clermont-Ferrand 2
Fisciano 2
Hangzhou 2
Hebei 2
Hefei 2
Hounslow 2
Jiaxing 2
Kharkiv 2
Kilburn 2
Lanzhou 2
Legnaro 2
Mabalacat 2
Naples 2
Ningbo 2
Pasig 2
Perugia 2
Phoenix 2
Rehovot 2
Rimini 2
Sale Marasino 2
Selargius 2
Sestu 2
Shanghai 2
Tokyo 2
Vimercate 2
Xian 2
Almaty 1
Apalit 1
Apiro 1
Bologna 1
Borås 1
Brentford 1
Totale 3.691
Salva come PNG Salva come JPEG
Nome #
Phase I trial of the oral smoothened inhibitor sonidegib in combination with paclitaxel in patients with advanced solid tumors 296
De-escalated therapy for HR+/HER2+ breast cancer patients with Ki67 response after 2 weeks letrozole: results of the PerELISA neoadjuvant study 179
First Prospective Multicenter Italian Study on the Impact of the 21-Gene Recurrence Score in Adjuvant Clinical Decisions for Patients with ER Positive/HER2 Negative Breast Cancer 140
BMI is an independent prognostic factor for late outcome in patients diagnosed with early breast cancer: A landmark survival analysis 128
Impact of 21-Gene Breast Cancer Assay on Treatment Decision for Patients with T1–T3, N0–N1, Estrogen Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Breast Cancer: Final Results of the Prospective Multicenter ROXANE Study 126
Patterns of Fertility Preservation and Pregnancy Outcome After Breast Cancer at a Large Comprehensive Cancer Center 123
Androgen receptor expression and association with distant disease-free survival in triple negative breast cancer: Analysis of 263 patients treated with standard therapy for stage I-III disease 123
The immune system and hormone-receptor positive breast cancer: Is it really a dead end? 122
Immune characterization of breast cancer metastases: Prognostic implications 122
Chemotherapy for advanced HER2-negative breast cancer: Can one algorithm fit all? 119
External validation of Modified Breast Graded Prognostic Assessment for breast cancer patients with brain metastases: A multicentric European experience 115
Use of scalp cooling device to prevent alopecia for early breast cancer patients receiving chemotherapy: A prospective study 114
HER2-enriched subtype and ERBB2 expression in HER2-positive breast cancer treated with dual HER2 blockade 107
Prognostic significance of AMPK activation in advanced stage colorectal cancer treated with chemotherapy plus bevacizumab. 105
Olaparib for the treatment of breast cancer 100
Beyond breast specific-Graded Prognostic Assessment in patients with brain metastases from breast cancer: treatment impact on outcome 98
Programmed Cell Death Ligand 1 in Breast Cancer: Technical Aspects, Prognostic Implications, and Predictive Value 97
Fat grafting for breast cancer patients: From basic science to clinical studies 96
Validation of the AJCC prognostic stage for HER2-positive breast cancer in the ShortHER trial 91
Clinicopathological and Treatment-Associated Prognostic Factors in Patients with Breast Cancer Leptomeningeal Metastases in Relation to Tumor Biology 90
Targeted next-generation sequencing identifies genomic abnormalities potentially driving the prognosis of early-stage invasive lobular breast carcinoma patients stratified according to a validated clinico-pathological model 81
Interaction of host immunity with HER2-targeted treatment and tumor heterogeneity in HER2-positive breast cancer 77
Hormone receptors status: a strong determinant of the kinetics of brain metastases occurrence compared with HER2 status in breast cancer 75
A case of Hodgkin lymphoma in a patient with a history of bone pain and an initial diagnosis of chronic osteomyelitis 67
Validation of Residual Proliferative Cancer Burden as a Predictor of Long-Term Outcome Following Neoadjuvant Chemotherapy in Patients with Hormone Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Breast Cancer 67
A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation 66
Biomarkers for HER2-positive metastatic breast cancer: Beyond hormone receptors 64
HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: A systematic review and meta-analysis 63
ESR1 Gene Mutation in Hormone Receptor-Positive HER2-Negative Metastatic Breast Cancer Patients: Concordance Between Tumor Tissue and Circulating Tumor DNA Analysis 63
Integration of tumour infiltrating lymphocytes, programmed cell-death ligand-1, CD8 and FOXP3 in prognostic models for triple-negative breast cancer: Analysis of 244 stage I–III patients treated with standard therapy 60
The tumor microenvironment of primitive and metastatic breast cancer: Implications for novel therapeutic strategies 60
Prognostic impact of proliferation for resected early stage ‘pure’ invasive lobular breast cancer: Cut-off analysis of Ki67 according to histology and clinical validation 59
Erbb2 mrna expression and response to ado-trastuzumab emtansine (T-dm1) in her2-positive breast cancer 59
Evolution of HER2-low expression from primary to recurrent breast cancer 56
PIK3CA Mutation in the ShortHER Randomized Adjuvant Trial for Patients with Early HER2+ Breast Cancer: Association with Prognosis and Integration with PAM50 Subtype 53
Impact of estrogen receptor levels on outcome in non-metastatic triple negative breast cancer patients treated with neoadjuvant/adjuvant chemotherapy 48
Neoadjuvant Chemotherapy and Immunotherapy in Luminal B-like Breast Cancer: Results of the Phase II GIADA Trial 48
A comprehensive profiling of the immune microenvironment of breast cancer brain metastases 47
Gene-expression signatures to inform neoadjuvant treatment decision in HR+/HER2− breast cancer: Available evidence and clinical implications 45
Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade 44
Tumor-infiltrating lymphocytes and molecular response after neoadjuvant therapy for HR+/HER2- breast cancer: results from two prospective trials 43
Impact of baseline and on-treatment glycemia on everolimus-exemestane efficacy in patients with hormone receptor-positive advanced breast cancer (EVERMET) 40
A prognostic model based on residual cancer burden and tumor-infiltrating lymphocytes on residual disease after neoadjuvant therapy in HER2+ breast cancer 39
Characterization of Gut Microbiome Composition in Patients with Triple-Negative Breast Cancer Treated with Neoadjuvant Chemotherapy 38
Olaparib for advanced breast cancer 38
Use of electronic administrative databases to measure quality indicators of breast cancer care: Experience of five regional oncology networks in Italy 38
Independent validation of the PAM50-based Chemo-Endocrine Score in hormonal receptor positive HER2-positive breast cancer treated with neoadjuvant therapy 36
HER2DX ERBB2 mRNA expression in advanced HER2-positive breast cancer treated with T-DM1 35
Neoadjuvant approach as a platform for treatment personalization: focus on HER2-positive and triple-negative breast cancer 34
Gastric metastases of breast cancer: Histopathological and molecular characterization of a single Institution case series 34
HER2-low-positive breast cancer: evolution from primary tumor to residual disease after neoadjuvant treatment 32
Immune microenvironment and intrinsic subtyping in hormone receptor-positive/HER2-negative breast cancer 30
Immune microenvironment characterisation and dynamics during anti-HER2-based neoadjuvant treatment in HER2-positive breast cancer 30
Development and validation of the new HER2DX assay for predicting pathological response and survival outcome in early-stage HER2-positive breast cancer 27
Oligometastatic breast cancer: Dissecting the clinical and biological uniqueness of this emerging entity. Can we pursue curability? 26
Incorporating weekly carboplatin in anthracycline and paclitaxel-containing neoadjuvant chemotherapy for triple-negative breast cancer: propensity-score matching analysis and TIL evaluation 24
HER2DX genomic test in HER2-positive/hormone receptor-positive breast cancer treated with neoadjuvant trastuzumab and pertuzumab: A correlative analysis from the PerELISA trial 23
T-DM1 versus pertuzumab, trastuzumab and a taxane as first-line therapy of early-relapsed HER2-positive metastatic breast cancer: an Italian multicenter observational study 23
Leptomeningeal metastases in patients with human epidermal growth factor receptor 2 positive breast cancer: Real-world data from a multicentric European cohort 19
Trastuzumab-lapatinib as neoadjuvant therapy for HER2-positive early breast cancer: Survival analyses of the CHER-Lob trial 19
PI3K/PTEN/mTOR pathway dynamic tracking and prognostic value in HR+/HER2- BC patients with residual disease after neoadjuvant chemotherapy: a cohort study 18
Association of HER2DX with pathological complete response and survival outcomes in HER2-positive breast cancer 18
Major advancements in metastatic breast cancer treatment: when expanding options means prolonging survival 17
Cardiac Safety of Adjuvant Trastuzumab and Paclitaxel for HER2+ early breast cancer patients published in Abstract Book of the 21th National Congress of Italian Association of Medical Oncology (AIOM) 25-27 October, 2019 - Rome, Italy Abstracts 16
Prognostic impact of extracranial disease control in HER2+ breast cancer-related brain metastases 16
Radiological response of leptomeningeal metastases according to revised RANO criteria is associated with overall survival in breast cancer patients 14
Peripheral blood lymphocytes predict clinical outcomes in hormone receptor-positive HER2-negative advanced breast cancer patients treated with CDK4/6 inhibitors 11
A systematic review of contemporary phase I trials in patients with lymphoma 9
Definition of High-Risk Early Hormone-Positive HER2-Negative Breast Cancer: A Consensus Review 9
Prognostic significance of HER2-low status in HR-positive/HER2-negative advanced breast cancer treated with CDK4/6 inhibitors 9
Intrathecal trastuzumab versus alternate routes of delivery for HER2-targeted therapies in patients with HER2+ breast cancer leptomeningeal metastases 8
BET inhibitors as potential anticancer agents 7
Gene-expression assays to tailor adjuvant endocrine therapy for HR+/HER2- breast cancer 7
Multidisciplinary management of HER2-positive breast cancer with brain metastases: An evidence-based pragmatic approach moving from pathophysiology to clinical data 5
Metastatic site patterns by intrinsic subtype and HER2DX in early HER2-positive breast cancer 4
The Impact of COVID-19 on Treatment Practices for Patients With Early Breast Cancer: A Cross-Sectional Study From a Large Cancer Center in Italy 4
Clinical applications of radiomics and deep learning in breast and lung cancer: A narrative literature review on current evidence and future perspectives 4
Survival after neoadjuvant therapy with trastuzumab-lapatinib and chemotherapy in patients with HER2-positive early breast cancer: a meta-analysis of randomized trials 3
Totale 4.500
Salva come PNG Salva come JPEG
Categoria #
all - tutte 20.789
article - articoli 20.789
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 41.578
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020746 0 0 29 142 57 32 58 89 110 112 52 65
2020/2021829 28 85 32 51 40 137 35 57 97 142 96 29
2021/2022850 50 62 83 46 103 81 75 49 46 38 54 163
2022/2023742 122 93 40 106 76 80 26 47 93 10 41 8
2023/2024811 44 60 55 43 44 75 50 255 15 41 56 73
2024/2025245 7 164 74 0 0 0 0 0 0 0 0 0
Totale 4.500